We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$7.44B
AUM Growth
+$696M
Cap. Flow
+$295M
Cap. Flow %
3.96%
Top 10 Hldgs %
25.63%
Holding
169
New
15
Increased
63
Reduced
24
Closed
17

Top Buys

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$57.2M
2
NCNO icon
nCino
NCNO
+$41.7M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$35.5M
4
ARGX icon
argenx
ARGX
+$33.8M
5
SHLS icon
Shoals Technologies Group
SHLS
+$31.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$52M
2
VRSK icon
Verisk Analytics
VRSK
+$37.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$26.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.1M
5
OKTA icon
Okta
OKTA
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 35.75%
2 Technology 29.25%
3 Industrials 12.31%
4 Consumer Discretionary 7.52%
5 Communication Services 5.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
76
Xenon Pharmaceuticals
XENE
$6.2B
$27.7M 0.37%
1,490,000
– –
VECT
77
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$26.6M 0.36%
+2,341,427
New +$35.5M
COMP icon
78
Compass
COMP
$8.56B
$26.6M 0.36%
+2,022,031
New +$31.5M
VCYT icon
79
Veracyte
VCYT
$4.77B
$26M 0.35%
651,000
– –
ROL icon
80
Rollins
ROL
$18.5B
$24.9M 0.33%
727,500
– –
ALXO icon
81
ALX Oncology
ALXO
$262M
$24.1M 0.32%
439,950
+349,950
+389% +$20.9M
BYND icon
82
Beyond Meat
BYND
$286M
$24M 0.32%
152,593
– –
CRDF icon
83
Cardiff Oncology
CRDF
$66.2M
$23.8M 0.32%
3,575,834
+1,792,346
+100% +$15.2M
RGEN icon
84
Repligen
RGEN
$7.03B
$23.8M 0.32%
119,000
– –
ISRG icon
85
Intuitive Surgical
ISRG
$126B
$23M 0.31%
75,000
– –
NBIX icon
86
Neurocrine Biosciences
NBIX
$18.7B
$22.9M 0.31%
235,000
-239,000
-50% -$22.9M
A icon
87
Agilent Technologies
A
$39.2B
$22.4M 0.3%
151,700
+28,000
+23% +$3.82M
TRML
88
DELISTED
Tourmaline Bio
TRML
$22.4M 0.3%
+156,109
New +$23.9M
ZNTL icon
89
Zentalis Pharmaceuticals
ZNTL
$350M
$22.4M 0.3%
420,400
-411,600
-49% -$22M
ETNB
90
DELISTED
89bio
ETNB
$21.3M 0.29%
1,137,092
-131,447
-10% -$2.93M
SHC icon
91
Sotera Health
SHC
$5.09B
$21.1M 0.28%
870,000
– –
MRTX
92
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$20.9M 0.28%
129,471
– –
PHAT icon
93
Phathom Pharmaceuticals
PHAT
$720M
$20.3M 0.27%
600,000
– –
BFLY icon
94
Butterfly Network
BFLY
$2.14B
$19.8M 0.27%
1,365,000
+247,000
+22% +$3.33M
FRLN
95
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$19.8M 0.27%
165,710
– –
CCXI
96
DELISTED
ChemoCentryx, Inc.
CCXI
$18.8M 0.25%
1,403,000
+843,000
+151% +$20.8M
FRC
97
DELISTED
First Republic Bank
FRC
$18.5M 0.25%
98,600
-600
-0.6% -$110K
STE icon
98
Steris
STE
$22.5B
$18.3M 0.25%
88,700
+21,100
+31% +$4.25M
KROS icon
99
Keros Therapeutics
KROS
$202M
$18.2M 0.24%
427,414
– –
NVT icon
100
nVent Electric
NVT
$23.4B
$17.5M 0.24%
+560,500
New +$17.3M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Eventide Asset Management held 169 positions worth $7.44B, up 10% from $6.75B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $295M of net new capital in Q2 2021, opening 15 new positions and adding to 63 existing holdings. Its largest new stake was nCino: 662,500 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 40% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Verisk Analytics, an estimated $37.6M trimmed.

  • Eventide Asset Management's largest Q2 2021 buy was nCino: 662,500 shares worth $39.7M.
  • Eventide Asset Management added most to Zymeworks in Q2 2021, an estimated $57.2M increase.
  • Eventide Asset Management's biggest Q2 2021 reduction was Verisk Analytics, cutting an estimated $37.6M.
  • Eventide Asset Management fully exited Sarepta Therapeutics in Q2 2021, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $7.44B portfolio in Q2 2021.
  • Eventide Asset Management opened 15 new positions and closed 17 in Q2 2021.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $7.44B.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.